303 related articles for article (PubMed ID: 36404344)
1. Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma.
Parker AL; Bowman E; Zingone A; Ryan BM; Cooper WA; Kohonen-Corish M; Harris CC; Cox TR
Genome Med; 2022 Nov; 14(1):126. PubMed ID: 36404344
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.
Ueda T; Aokage K; Nishikawa H; Neri S; Nakamura H; Sugano M; Tane K; Miyoshi T; Kojima M; Fujii S; Kuwata T; Ochiai A; Kusumoto M; Suzuki K; Tsuboi M; Ishii G
J Cancer Res Clin Oncol; 2018 May; 144(5):835-844. PubMed ID: 29435735
[TBL] [Abstract][Full Text] [Related]
3. Role of the extracellular matrix in variations of invasive pathways in lung cancers.
de Sá VK; Carvalho L; Gomes A; Alarcão A; Silva MR; Couceiro P; Sousa V; Soares FA; Capelozzi VL
Braz J Med Biol Res; 2013 Jan; 46(1):21-31. PubMed ID: 23314337
[TBL] [Abstract][Full Text] [Related]
4. Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients.
Takahashi Y; Ishii G; Taira T; Fujii S; Yanagi S; Hishida T; Yoshida J; Nishimura M; Nomori H; Nagai K; Ochiai A
J Thorac Oncol; 2011 Sep; 6(9):1460-7. PubMed ID: 21849853
[TBL] [Abstract][Full Text] [Related]
5. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
[TBL] [Abstract][Full Text] [Related]
6. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
7. The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma.
Lin MW; Huang YL; Yang CY; Kuo SW; Wu CT; Chang YL
Ann Surg Oncol; 2019 Jan; 26(1):217-229. PubMed ID: 30456676
[TBL] [Abstract][Full Text] [Related]
8. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
9. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation distinguishes basaloid variant of lung squamous cell carcinoma.
Keyhanian K; Phillips WJ; Yeung BS; Gomes M; Lo B; Sekhon HS
Diagn Pathol; 2022 May; 17(1):46. PubMed ID: 35538551
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma.
Li J; Chen H; Li X; Wang L; Gao A; Zhang P; Lin W; Gao W; Yang D; Guo X; Liu J; Dang Q; Sun Y
Mol Med Rep; 2017 Aug; 16(2):1643-1652. PubMed ID: 28656229
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma.
Tanaka Y; Nakai T; Suzuki A; Kagawa Y; Noritake O; Taki T; Hashimoto H; Sakai T; Shibata Y; Izumi H; Nosaki K; Udagawa H; Zenke Y; Matsumoto S; Yoh K; Miyazaki S; Sakamoto N; Sakashita S; Kojima M; Watanbe R; Tsuboi M; Goto K; Ishii G
Cancer Immunol Immunother; 2023 Jul; 72(7):2205-2215. PubMed ID: 36862151
[TBL] [Abstract][Full Text] [Related]
13. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
14. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.
Wu D; Pang Y; Wilkerson MD; Wang D; Hammerman PS; Liu JS
Br J Cancer; 2013 Sep; 109(6):1599-608. PubMed ID: 24002593
[TBL] [Abstract][Full Text] [Related]
15. Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.
Takanashi Y; Funai K; Eto F; Mizuno K; Kawase A; Tao H; Kitamoto T; Takahashi Y; Sugimura H; Setou M; Kahyo T; Shiiya N
BMC Cancer; 2021 Nov; 21(1):1232. PubMed ID: 34789180
[TBL] [Abstract][Full Text] [Related]
16. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
[TBL] [Abstract][Full Text] [Related]
17. A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.
Hata A; Nakajima T; Matsusaka K; Fukuyo M; Morimoto J; Yamamoto T; Sakairi Y; Rahmutulla B; Ota S; Wada H; Suzuki H; Matsubara H; Yoshino I; Kaneda A
Int J Cancer; 2020 Jan; 146(2):388-399. PubMed ID: 31241180
[TBL] [Abstract][Full Text] [Related]
18. Developing a dormancy-associated ECM signature in TNBC that is linked to immunosuppressive tumor microenvironment and selective sensitivity to MAPK inhibitors.
Dong Y; Bai J; Zhou J
Heliyon; 2024 Jun; 10(11):e32106. PubMed ID: 38868025
[TBL] [Abstract][Full Text] [Related]
19. Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients.
Masuda R; Kijima H; Imamura N; Aruga N; Nakamura Y; Masuda D; Takeichi H; Kato N; Nakagawa T; Tanaka M; Inokuchi S; Iwazaki M
Mol Med Rep; 2012 Nov; 6(5):937-43. PubMed ID: 22940760
[TBL] [Abstract][Full Text] [Related]
20. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
Nishino M; Hoang MP; Della Pelle P; Morales-Oyarvide V; Huynh TG; Mark EJ; Mino-Kenudson M
Cancer Cytopathol; 2016 Jul; 124(7):472-84. PubMed ID: 27412420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
